Deciphera Pharmaceuticals
- Partner Level
- Platinum
- Company Headquarters
- Waltham, MA
- Website
- Visit Site
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
Patient Support Program
Deciphera AccessPoint
DecipheraAccessPoint.com
1-833-4DACCES (1-833-432-2237) Monday–Friday 8AM–8PM ET
1-833-DCPH-FAX (1-833-327-4329)
Email info@decipheraaccesspoint.com to schedule a call back
